Australian medical company 4DMedical reported on Monday the receipt of clearance from the US Food & Drug Administration to market its XV Technology that rapidly and automatically analyses any functional lung impairment including COVID-19 from a single X-ray.

A patented four-dimensional lung imaging process, the XV Technology provides critical information about the functional and structural state of a patient's lungs in the treatment of illnesses including COVID-19, asthma, chronic obstructive pulmonary disease, cystic fibrosis as well as lung cancer, added the company.

The company said the XV Technology process is a software-as-a-service (SaaS) diagnostic tool, available through secure cloud subscription, and can be implemented immediately, utilizing existing hospital and clinical infrastructure with no capital expenditure or training required.

According to the company, the software generates a ventilation report within three hours and sends it to the hospital to enable clinicians to determine the most effective treatment course of action and allocation of finite hospital resources. The technology is supported by 15 years of preclinical and clinical trials and ongoing collaborations with leading hospitals worldwide.